Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

195.72 -5.46 (-2.71%)

Streaming Delayed Price Updated: 1:44 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

57 58 Next >

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention ↗

November 23, 2022

The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Via Benzinga

Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth ↗

November 22, 2022

Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn...

Via Talk Markets

TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO ↗

November 21, 2022

Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO.

Via InvestorPlace

Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10 ↗

November 10, 2022

Looking for a clear three-wave move pullback before considering any long-term longs.

Via Talk Markets

Is Biogen Poised for a Bull Run? ↗

November 03, 2022

Biogen has been a market-beating stock this year, but can that trend continue?

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

November 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Stocks to Avoid Right Now ↗

November 17, 2022

Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.

Via The Motley Fool

CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB

November 17, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Up Today? ↗

November 14, 2022

Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.

Via InvestorPlace

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Why Is AST SpaceMobile (ASTS) Moving Today? ↗

November 14, 2022

AST SpaceMobile (ASTS) stock is a hot topic on Monday as investors react to the company setting up its BlueWalker 3 satellite array.

Via InvestorPlace

Why Is Biogen (BIIB) Stock Up Today? ↗

November 14, 2022

Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.

Via InvestorPlace

What's Going On With Biogen Stock Today? ↗

November 14, 2022

Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies.

Via Benzinga

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗

November 14, 2022

Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.

Via Investor's Business Daily

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗

November 14, 2022

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...

Via Benzinga

Why Shares Of Eli Lilly And Biogen Are Rallying Today ↗

November 14, 2022

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.

Via Benzinga

Why Are Healthcare Stocks Down Today? ↗

November 11, 2022

Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors.

Via InvestorPlace

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗

November 10, 2022

Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.

Via Investor's Business Daily

Biogen Names Christopher Viehbacher President and Chief Executive Officer

November 10, 2022

Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies

From Biogen Inc.

Via GlobeNewswire

The Power of McKinsey ↗

November 09, 2022

Author Michael Forsythe talks about his new book, "When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm."

Via The Motley Fool

Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday ↗

November 01, 2022

Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday.

Via Benzinga

Don't Get Used to Lower Medicare Part B Premiums -- Here's Why ↗

October 29, 2022

Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review ↗

October 28, 2022

The Dow and S&P 500 moved above a key level while the Nasdaq rose.

Via Investor's Business Daily

Is Biogen Stock a Buy Now That Guidance Has Been Raised?

October 26, 2022

Biogen stock (NASDAQ:BIIB) continues to get excellent news. On Tuesday, the pharmaceutical company released its third-quarter results, and for the first time in a long time, investors found something...

Via PressReach

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022 ↗

October 26, 2022

Upgrades

Via Benzinga

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

October 26, 2022

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.